



The Science of RealW8

Dwight Lundell M.D.

Over the last 20 years, obesity rates have dramatically increased in the United States, (1) and of the approximately 2/3 adults in the United States who are overweight, more than half of them—more than 72 million—are considered obese (2,3).

In the last decade alone the rate of diabetes cases has nearly doubled (4). Most alarming is the increase in overweight and obese children. It is now estimated that one in five children in the United States is overweight (5).

Obesity is closely associated with myriad chronic diseases; heart disease, type II diabetes and some cancers as well as psychiatric disorders such as depression and hopelessness. (6, 7, 8) The health care costs in the United States alone are \$147 billion, the costs in absenteeism and lost productivity is at least that much. (9)

- While the physics of “calories in calories out” is not in question, it does not explain the why.
- Why do we eat more than we burn?
- Why do we ignore the health consequences associated with excess fat storage?
- Why does the medical advice to “eat less move more” not work?
- Why are some calories more uniquely fattening than others?
- Why do people who can control many other aspects of their lives not achieve control over their caloric intake?
- Why, with all the advances in science, computers, and miracles of modern medicine have we not been able to solve this excess weight problem?
- Why, when our bodies control everything in narrow ranges to achieve normal metabolism do we not have symptoms when blood sugars are out of the normal and healthy range?
- Why and how do these elevated blood sugars harm tissues, organs and DNA?
- Why are we so fat and what can we do about it?

Over the last 50,000 years humans have benefitted from an ability to store fat, and this ability has been the key to man’s survival. The ability to store fat meant that man could carry enough energy to survive when food was scarce. Seasonal variations in food quality, quantity and variety could be sustained by the ability to carry large stores of calories as fat.

In the last 100 years changes in the human diet and lifestyle, with abundant food and increased productivity, have overwhelmed our genome’s ability to adapt to these changes. As a consequence, billions of people around the world are now overly fat (10).

The thing that has most drastically changed in our environment over the last 200 years is the amount of sugar we consume. In 1811 we consumed about 20 pounds of sugar per person, in 1911 we consumed about 90 lbs per person and in 2011 we consumed 180 pounds of sugar per person per year (11).

This amount of sugar in the diet has clearly overwhelmed the ability of the body to control blood sugar and fat storage.

Sugar in the diet is rapidly digested and absorbed into the bloodstream as glucose, blood glucose or blood sugar.

To facilitate the complex electrochemical reactions that constitute life, the reagents must be controlled in a narrow range both inside and outside of the cell. There are chemical and hormonal mechanisms to regulate these elements, and if they get very far from the normal range,

symptoms, dysfunction and even death of tissue or the whole organism can occur.

One must only hold their breath for a few moments to experience the powerful forces that regulate oxygen levels in the blood or experience a fever to know the symptoms when body temperature varies from normal.

Blood sugar is controlled primarily by the hormones insulin and glucagon, normally in narrow range. If blood sugar falls too low, symptoms of fainting, lightheadedness, blackouts and even death occur. However, blood sugar can be elevated far beyond normal without symptoms. From an evolutionary view this would be acceptable; not to have a negative consequence for doing the very thing that would ensure survival—consuming quantities of food when available to be stored for later use. Even if there was some injury it would be worth the damage for the greater goal of survival. If Paleolithic man came upon a beehive full of honey or a large quantity of fruit in season he consumed it and would not expect to be made ill by that consumption as temporary elevation of blood sugar facilitated the conversion of the glucose to fat for storage in the fat cells.

The modern diet with excess quantities of sugar and refined grains creates a challenge for the metabolism. If this only happened occasionally it would not create adverse health consequences, but when it happens multiple times per day, heart disease, dyslipidemia, obesity, premature aging, and hypertension are common (11)

A glucose tolerance test to diagnose diabetes is done by giving the patient a maximum of 75 grams of glucose after a 12 hour fast and then testing the blood sugar over the next 2 hours. If the blood glucose is over 200mg/dL at 2 hours, a diagnosis of diabetes is warranted. Ideally the glucose would not go over 120mg/dL at 2 hours. Fasting blood glucose over 100mg/dL is abnormal and a level over 120 is considered diagnostic for diabetes. Normal fasting glucose should be between 70 and 85 mg/dL.


When we consider that the 20 oz soft drink contains 65 grams of sugar and a medium order of fries has 45 grams and that the common 44 oz soft drink contains 128 grams, we often get a super maximal glucose tolerance test multiple times per day without medical supervision.

These sugar spikes often go undetected because there are no symptoms, and testing is usually done only in a fasting state, not after meals or snacks.


The frequency of the spikes and the damage caused is well documented (12-19). For example, the risk of heart attack increases by 58% for each 21mg/dL increase in after-meal blood sugar (18).

Over 80% of adults have fasting blood glucose over 85mg/dL, which many consider abnormal and would reflect severely elevated blood sugars throughout a normal day of frequent high-sugar meals and snacks (20, 21).

The evidence is clear that sugar spikes are common, especially with current diet and lifestyles.



Diabetic Glucose Tolerance Curve



Typical Glucose Tolerance Curve With Only One Ingredient Of RealW8

What are the consequences of these sugar spikes?

Diabetes is characterized by frequent and significantly elevated blood sugar spikes, and diabetes is marked by a unique set of tissues that are damaged by these sugar spikes. The tissues most vulnerable to elevated blood sugar are those in the eye, the kidney, the nerve and the lining of the blood vessel. Elevated blood sugar bathes all cells in the body with excess glucose and most cells can control the amount of glucose entering because of insulin receptors. However, due to the lack of the most common insulin receptors these cells are at the mercy of the blood glucose, with the levels in the cells the same inside as outside. The common pathway for the damage is oxidative stress because the energy-producing mitochondrion is overloaded with fuel and produces excess free radicals (22).

The oxidative stress leads to cell damage and death, which triggers the inflammatory cascade in these tissues. This is exacerbated by inflammation from the overloaded fat cells that are injured, dying and producing inflammatory cytokines that are then circulated throughout the body.

The evidence is then clear that the sugar spikes (postprandial hyperglycemia) induce damage to tissues and organs and are central to the storage of excess fat, yet even with that knowledge we cannot seem to control the sugar spikes.

An increasing body of evidence is accumulating that shows these sugar spikes are also addictive (23).

Addiction is often used as a synonym for dependence. Drug dependence is characterized by compulsive, sometimes uncontrollable, behaviors that occur at the expense of other activities and intensify with repeated access, as defined by DSM-IV-TR, American Psychiatric Association.

Dependence is diagnosed when three or more of the following seven criteria are met;

- 1) Tolerance, as defined by either of the following: a) a need for markedly increased amounts of the substance to achieve desired effect, b) markedly diminished affect with continued use of the same amount of the substance.
- 2) Withdrawal, as manifested by either of the following: a) characteristic withdrawal symptoms for the substance, b) the same substance is taken to relieve or avoid withdrawal symptoms.
- 3) The substance is often taken in larger amounts or over a longer period of time than was intended.
- 4) There is a persistent desire or unsuccessful efforts to cut down or control the substance use.
- 5) A great deal of time is spent in activities necessary to obtain the substance, use the substance, or recover from its effects.
- 6) Important social, occupational, or recreational activities are given up or reduced because of substance use.
- 7) The substance use is continued despite the knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance.

The Yale Food Addiction Scale (YFAS) has recently been developed and validated as a reliable tool to assess addictive behaviors in a population that would typically deny or minimize those behaviors (24).

The behavioral and neurochemical changes in the brain are very similar to those of drug addiction and can be demonstrated by typical changes in dopamine release and receptors, opioid receptors and blockers and acetylcholine systems. These alterations can be demonstrated biochemically and with brain imaging (23).

With clear evidence that sugar spikes, or more properly postprandial hyperglycemia, are common, damaging and addictive (25-29), the obvious question is what can be done about them.

The willful reduction in dietary carbohydrate intake should be obvious. This has been written about since Banting's Letter on Corpulence was published in 1869 and was continued by many others until the 70's when it was overwhelmed by the low fat theory and carbohydrates were promoted as "Heart Healthy" by medicine, governmental authorities and by the big food manufacturers who heavily

produced and promoted high-sugar and carbohydrate-processed foods to their great profit.

Against this background of a decidedly hostile environment, it seemed that the solution would be to intervene in a way that prevented or moderated the sugar spikes, thereby solving the problem of addiction, fat storage and ill health.

A search for natural compounds that would modify the digestion, absorption and metabolism of glucose was undertaken.

Five plant based products were identified; each had a significant body of scientific evidence indicating that they would change the digestion, absorption and metabolism of glucose.

The first compound is a concentrated extract of the raw or unroasted coffee bean. The extract has been shown to lower sugar spikes (30), reduce diabetes (35, 39) and generally modify glucose metabolism to reduce sugar spikes (31-51).

The second is an extract of a specific seaweed that reduces the digestion of both fat and glucose, (55) and provides key antioxidants (56-60).


The third is from the prickly pear leaf, which has been shown to reduce diabetes, LDL oxidation and provide key antioxidants (61-152).

The fourth is berberine, which has been used for thousands of years by Chinese Traditional medical practitioners as a tool to assist people with digestive issues and diabetes. Berberine caught worldwide attention when it's purified and concentrated form was clinically researched and found to have the same results as one of the most popular prescription medications, without any of the devastating adverse side effects. Berberine works in several ways to delay the absorption and improve the metabolism of carbohydrates.


The fifth is Phaseolus Vulgaris (an extract from white kidney beans). Phaseolus Vulgaris works by drastically inhibiting the key enzyme that breaks down sugar and carbohydrates so they can be absorbed from the intestine, this forces them to be broken down in a different place and in a different way, thus avoiding those deadly "sugar spikes" that normally would occur with the consumption of simple carbohydrates. Improved extraction and purification methods have recently enhanced its effectiveness.

RealW8 is the first weight loss supplement to combine these five clinically proven compounds in a way that maximizes their efficacy.

RealW8 is the only weight loss supplement that attacks the problem of sugar spikes (post prandial hyperglycemia) to promote a reduction in the addictive properties of carbohydrates and the health consequences that follow from the consumption of them.



Typical Glucose Tolerance Curve With Only One Ingredient Of RealW8



Typical Glucose Tolerance Curve After Carbohydrate Meal
Typical Glucose Tolerance Curve With Only One Ingredient Of RealW8

Bibliography

1. US Obesity Trends 1985-2007 CDC
2. National Health and Nutrition Examination Survey (NHANES 2001-2004)
3. National Center for Health Statistics survey (2005-2006)
4. CDC State-by-State review October 2008
5. Prevalence of overweight among children and adolescents ages 6-19 years. Source: CDC/NCHS and NHANES http://www.obesity.org/information/childhood_overweight.asp
6. Must A, Spandano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. *JAMA* 1999;282:1523-9.
7. Kolotkin RL, Crosby RD, Gress RE, Hunt SC, Engel SG, Adams TD. Health and health-related quality of life: differences between men and women who seek gastric bypass surgery. *Surg Obes Relat Dis* 2008;4:651-8.
8. Valtonen M, Laaksonen DE, Tolmunen T, et al. Hopelessness- novel facet of the metabolic syndrome in men. *Scand J Public Health* 2008;36:795-802.
9. Finkelstein EA, Trogon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer- and service-specific estimates. *Health Aff* 2009;28:w822-31.
10. Heber D. *AM J Clin Nutr* 2010;91:2805-35.
11. Howard B. *Circulation* 2002;106:523-7.
12. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. *Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe. Lancet.* 1999 Aug 21;354(9179):617-21.
13. Nakagami T. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. *Diabetologia.* 2004 Mar;47(3):385-94.
14. Miura K, Kitahara Y, Yamagishi S. Combination therapy with nateglinide and vildagliptin improves postprandial metabolic derangements in Zucker fatty rats. *Horm Metab Res.* 2010 Sep;42(10):731-5.
15. Monnier L, Colette C. Glycemic variability: should we and can we prevent it? *Diabetes Care.* 2008 Feb;31 Suppl 2:S150-4.
16. Monnier L, Colette C, Owens DR. Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? *J Diabetes Sci Technol.* 2008 Nov;2(6):1094-100.
17. Triggler CR. The early effects of elevated glucose on endothelial function as a target in the treatment of type 2 diabetes. *Timely Top Med Cardiovasc Dis.* 2008;12:E3.
18. Gerstein HC, Pais P, Pogue J, Yusuf S. Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study. *J Am Coll Cardiol.* 1999 Mar;33(3):612-9.
19. Lin HJ, Lee BC, Ho YL, et al. Postprandial glucose improves the risk prediction of cardiovascular death beyond the metabolic syndrome in the nondiabetic population. *Diabetes Care.* 2009 Sep;32(9):1721-6.
20. Nichols GA, Hillier TA, Brown JB. Normal fasting plasma glucose and risk of type 2 diabetes diagnosis. *Am J Med.* 2008 Jun;121(6):519-24.
21. Kato M, Noda M, Suga H, Matsumoto M, Kanazawa Y. Fasting plasma glucose and incidence of diabetes- implication for the threshold for impaired fasting glucose: results from the population-based Omiya MA cohort study. *J Atheroscler Thromb.* 2009;16(6):857-61.
22. Brownlee M *Diabetes*:54;1615-1625
23. Avena *Neurosci Biobehav*
24. *Addiction* (in Press)
25. Nichols GA, Hillier TA, Brown JB. Normal fasting plasma glucose and risk of type 2 diabetes diagnosis. *Am J Med.* 2008 Jun;121(6):519-24.
26. Kato M, Noda M, Suga H, Matsumoto M, Kanazawa Y. Fasting plasma glucose and incidence of diabetes- implication for the threshold for impaired fasting glucose: results from the population- based Omiya MA cohort study. *J Atheroscler Thromb.* 2009;16(6):857-61.
27. Available at: <http://diabetes.niddk.nih.gov/dm/pubs/diagnosis/#diagnosis>. Accessed August 15, 2011.
28. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. *Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe. Lancet.* 1999 Aug 21;354(9179):617-21.
29. Nakagami T. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. *Diabetologia.* 2004 Mar;47(3):385-94.
30. Nagendran MV. Effect of green coffee bean extract (GCE), High in Chlorogenic Acids, on Glucose Metabolism. Poster presentation number:45-LB-P. Obesity 2011, the 29th Annual Scientific Meeting of the Obesity Society. Orlando, Florida October 1-5, 2011.
31. Hemmerle H, Burger HJ, Below P, et al. Chlorogenic acid and synthetic chlorogenic acid derivatives: novel inhibitors of hepatic glucose-6-phosphatetranslocase. *J Med Chem.* 1997 Jan 17;40(2):137-45.
32. Arion WJ, Canfield WK, Ramos FC, et al. Chlorogenic acid and hydroxynitrobenzaldehyde: new inhibitors of hepatic glucose 6-phosphatase. *Arch Biochem Biophys.* 1997 Mar 15;339(2):315-22.
33. Rizza RA. Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy. *Diabetes.* 2010 Nov;59(11):2697-707.

34. Henry-Vitrac C, Ibarra A, Roller M, Merillon JM, Vitrac X. Contribution of chlorogenic acids to the inhibition of human hepatic glucose-6-phosphatase activity in vitro by Svetol, a standardized decaffeinated green coffee extract. *J Agric Food Chem.* 2010 Apr 14;58(7):4141-4.
35. Salazar-Martinez E, Willett WC, Ascherio A, et al. Coffee consumption and risk for type 2 diabetes mellitus. *Ann Intern Med.* 2004 Jan 6;140(1):1-8.
36. Pereira MA, Parker ED, Folsom AR. Coffee consumption and risk of type 2 diabetes mellitus: an 11-year prospective study of 28,812 postmenopausal women. *Arch Intern Med.* 2006 Jun 26;166(12):1311-6.
37. Johnston KL, Clifford MN, Morgan LM. Coffee acutely modifies gastrointestinal hormone secretion and glucose tolerance in humans: glycemic effects of chlorogenic acid and caffeine. *Am J Clin Nutr.* 2003 Oct;78(4):728-33.
38. Bidel S, Hu G, Sundvall J, Kaprio J, Tuomilehto J. Effects of coffee consumption on glucose tolerance, serum glucose and insulin levels- a cross-sectional analysis. *Horm Metab Res.* Jan;38(1):38-43.
39. Van Dam RM, Feskens EJM. Coffee consumption and risk of type 2 diabetes mellitus. *Lancet.* 2002 Nov 9;360(9344):1477-8.
40. Murase T, Misawa K, Minegishi Y, Aoki M, Ominami H, Suzuki Y, Hase T. Coffee polyphenols suppress diet-induced body fat accumulation by downregulating SREBP-1c and related molecules in C57BL/6J mice. *Am J Physiol Endocrinol Metab.* 2011 Jan;300(1):E122-33.
41. Henry-Vitrac C, Ibarra A, Roller M, Merillon JM, Vitrac X. Contribution of chlorogenic acids to the inhibition of human hepatic glucose-6-phosphatase activity in vitro by Svetol, a standardized decaffeinated green coffee extract. *J Agric Food Chem.* 2010 Apr 14;58(7):4141-4.
42. Andrade-Cetto A, Vazquez RC. Gluconeogenesis inhibition and phytochemical composition of two *Cecropia* species. *J Ethnopharmacol.* 2010 Jul 6;130(1):93-7.
43. Bassoli BK, Cassolla P, Borba-Murad GR, et al. Chlorogenic acid reduces the plasma glucose peak in the oral glucose tolerance test: effects on hepatic glucose release and glycaemia. *Cell Biochem Funct.* 2008 Apr;26(3):320-8.
44. Isikawa A, Yamashita H, Hiemori M, et al. Characterization of inhibitors of postprandial hyperglycemia from the leaves of *Nerium indicum*. *J Nutr Sci Vitaminol (Tokyo).* 2007 Apr;53(2):166-73.
45. Alonso-Castro AJ, Miranda-Torres AC, Gonzalez-Chavez MM, Salazar-Olivo LA. *Cecropia obtusifolia* Bertol and its active compound, chlorogenic acid, stimulate 2-NBDglucose uptake in both insulin-sensitive and insulin-resistant 3T3 adipocytes. *J Ethnopharmacol.* 2008 Dec 8;120(3):458-64.
46. Rodriguez de Sotillo DV, Hadley M, Sotillo JE. Insulin receptor exon 11 +/- is expressed in Zucker (fa/fa) rats, and chlorogenic acid modifies their plasma insulin and liver protein and DNA. *J Nutr Biochem.* 2006 Jan;17(1):63-71.
47. Herrera-Arellano A, Aguilar-Santamaria L, Garcia-Hernandez B, Nicasio-Torres P, Tortoriello J. Clinical trial of *Cecropia obtusifolia* and *Marrubium vulgare* leaf extracts on blood glucose and serum lipids in type 2 diabetes. *Phytomedicine.* 2004 Nov;11(7-8):561-6.
48. Thom E. The effect of chlorogenic acid enriched coffee on glucose absorption in healthy volunteers and its effect on body mass when used long-term in overweight and obese people. *J Int Med Res.* 2007 Nov-Dec;35(6):900-8.
49. Van Dijk AE, Olthof MR, Meeuse JC, Seebus E, Heine RJ, van Dam RM. Acute effects of decaffeinated coffee and the major coffee components chlorogenic acid and trigonelline on glucose tolerance. *Diabetes Care.* 2009 Jun;32(6):1023-5.
50. Zhang LT, Chang CQ, Liu Y, Chen ZM. Effect of chlorogenic acid on disordered glucose and lipid metabolism in db/db mice and its mechanism. *Zhongguo Yi Xue Ke Xue Yuan Xue Bao.* 2011 Jun;33(3):281-6.
51. Personal Communication
52. Antioxidant and pro-oxidant activities of the brown algae, *Laminaria digitata*, *Himantalia elongata*, *Fucus vesiculosus*, *Fucus serratus* and *Ascophyllum nodosum*. B. Le Tutour et al. *Journal of Applied Phycology* Vol. 10, N'2 p121-129.
53. Potential antioxidant capacity of sulfated polysaccharides from the edible marine brown seaweed *Fucus Vesiculosus*. Ruperez P. et al., *J Agric Food Chem.* 2002 Feb 13;50(4):840-5.
54. Evaluation of antioxidative activity of extracts from a brown seaweed, *Sargassum siliquastrum*. Lim SN et al., *J Agric Food Chem.* 2002 Jun 19;50(13):3862-6.
55. Phlorotannins from the brown alga *Cystophora torulosa*, Glombitza K.W. And Hauperich S. (1997), *Phytochemistry*, 46, 735-740.
56. Phlorotannins, brown algal polyphenols, Ragan M.A. And Glombitza K.W. (1986), *Progress in Phycological Research*, 4, 129-241.
57. Jill Stansbury. Medicinal Uses of *Opuntia* (Prickly Pear). Southwest Conference on Botanical Medicine, April 10-11, 2010. Southwest College of Naturopathic Medicine: Tempe, Arizona.
58. Li CY, Cheng XS, Cui MZ, Yan YG. [Regulative effect of *Opuntia* powder on blood lipids in rats and its mechanism]. 2005 May; 30(9):694-6. PubMed; PMID: 16075737.
59. Fernandez ML, Lin EC, Trejo A, McNamara DJ. Prickly pear (*Opuntia* sp.) pectin alters hepatic cholesterol metabolism without affecting cholesterol absorption in guinea pigs fed a hypercholesterolemic diet. *J Nutr.* 1994 Jun; 124(6): 817-24. PubMed; PMID:8207539.
60. Cárdenas Medellín ML, Serna Saldívar SO, Velazco de la Garza J. [Effect of raw and cooked nopal (*Opuntia ficus indica*) ingestion on growth and profile of total cholesterol, lipoproteins, and blood glucose in rats]. *Arch Latinoam Nutr.* 1998 Dec; 48(4):316-23. PubMed; PMID:10347696.

61. Fernandez ML, Lin EC, Trejo A, McNamara DJ. Prickly pear (*Opuntia* sp.) pectin reverses low density lipoprotein receptor suppression induced by a hypercholesterolemic diet in guinea pigs. *J Nutr.* 1992 Dec; 122(12):2330-40. PubMed; PMID:1333520.
62. Linares E, Thimonier C, Degre M. The effect of *NeOpuntia* on blood lipid parameters-risk factors for the metabolic syndrome (syndrome X). *Adv Ther.* 2007 Sep-Oct;24(5):1115-25. PubMed; PMID:18029338.
63. Ennouri M, Fetoui H, Bourret E, Zeghal N, Guermazi F, Attia H. Evaluation of some biologic parameters of *Opuntia ficus indica*. 2. Influence of seed supplemented diet on rats. *Bioresour Technol.* 2006 Nov;97(16):2136-40. Epub 2005 Nov 14. PubMed; PMID:16290138.
64. Palumbo B, Efthimiou Y, Oguogho A, Budinsky A, Palumbo R, Sinzinger H. Prickly pear induces upregulation of liver LDL binding in familial heterozygous hypercholesterolemia. *Nucl Med Rev Cent East Eur.* 2003;6(1):35-9. PubMed; PMID: 14600931.
65. Budinsky A, Wolfram R, Oguogho A, Ethimiou Y, Stamatopoulos Y, Sinzinger H. Regular ingestion of *Opuntia robusta* lowers oxidation injury. *Prostaglandins Leukot Essent Fatty Acids.* 2001 Jul;65(1):45-50. PubMed; PMID: 11487308.
66. MARIO ALLEGRA, LUISA TESORIERE, MARIA A. LIVREA. Betanin inhibits the myeloperoxidase/nitrite-induced oxidation of human low density lipoproteins. *GFRR* 203785-14/10/2006-SWAPNA-224908. *Free Radical Research*,2006;00(0):1-7.
67. Whitney MT. Nopal plant normalizes blood sugar, treats diabetes, boosts insulin sensitivity. *NaturalNews.com* Feb 20, 2007.
68. Miguel Angel Gutierrez. (1998) "Medicinal Use of The Latin Food Staple Nopales: The Prickly Pear Cactus", *Nutrition Bytes*: Vol. 4, No. 2, Article 3, 1998. <http://repositories.cdlib.org/uclabiolchem/nutritionbytes/vol4/iss2/art3>.
69. Frati-Munari AC, Gordillo BE, Altamirano P, Ariza CR. Hypoglycemic effect of *Opuntia streptacantha* Lemaire in NIDDM. *Diabetes Care.* 1988 Jan;11(1):63-6. PubMed; PMID: 3276479.
70. Jose Luis Lopez Jr. (2007) "Use of *Opuntia* Cactus as a Hypoglycemic Agent in Managing Type 2 Diabetes Mellitus among Mexican American Patients", *Nutrition Bytes*: Vol. 12: No. 1 Article 2. <http://repositories.cdlib.org/uclabiolchem/nutritionbytes/vol12/iss1/art2>.
71. Francisco M. Goycoolea, Adrianna Cárdenas. Pectins from *Opuntia* spp.: A Short Review. *J.PACD-2003.* Pages 17-29.
72. Frati-Munari AC, Del Valle-Martinez LM, Ariza-Andraca CR, Islas-Andrade S, Chávez-Negrete A. [Hypoglycemic action of different doses of nopal (*Opuntia streptacantha* Lemaire) in patients with type II diabetes mellitus]. *Arch Invest Med (Mex)* 1989 Apr-Jun; 20(2):197-201. PubMed; PMID:2557805.
73. Frati-Munari AC, Rios Gil U, Ariza-Andraca CR, Islas Andrade S, Lopez Ledesma R. [Duration of the hypoglycemic action of *Opuntia streptacantha* Lem.]. *Arch Invest Med (Mex).* 1989 Oct-Dec; 20(4): 297-300. PubMed; PMID:2488768.
74. Frati-Munari AC, Licona-Quesada R, Araiza-Andraca CR, López Ledesma R, Chávez-Negrete A. [Activity of *Opuntia streptacantha* in healthy individuals with induced hyperglycemia]. *Arch Invest Med (Mex)* 1990 Apr-Jun; 21(2):99-102. PubMed; PMID: 2103713.
75. Frati-Munari AC, Vera Lastro O, Ariza-Andraca CR. [Evaluation of nopal capsules in diabetes mellitus]. *GAc Med Mex.* 1992 Jul-Aug; 128(4):431-6. PubMed; PMID:1307994.
76. Bwititi PT, Machakaire T, Nhachi CB, Musabayane CT. Effects of *Opuntia megacantha* leaves extract on renal electrolyte and fluid handling in streptozotocin (STZ)-diabetic rats. *Ren Fail.* 2001 Mar;23(2):149-58. PubMed; PMID:11417947.
77. Trejo-González A, Gabriel-Ortiz G, Puebla-Pérez AM, Huízar-Contreras MD, Munguía-Mazariegos MR, Mejía-Arreguín S, Calva E. A purified extract from prickly pear cactus (*Opuntia fuliginosa*) controls experimentally induced diabetes in rats. *J Ethnopharmacol.* 1996 Dec;55(1):27-33. PubMed; PMID: 9121164.
78. Wolfram RM, Efthimiou Y, Stomatopoulos Y, Sinzinger H. Effect of prickly pear (*Opuntia robusta*) on glucose- and lipid-metabolism in non-diabetics with hyperlipidemia—a pilot study. *Wien Klin Wochenschr.* 2002 Oct 31;114(19-20):840-6. PubMed; PMID: 12503475.
79. Laurenz JC, Collier CC, Kuti JO. Hypoglycaemic effect of *Opuntia lindheimeri* Englem in a diabetic pig model. *Phytother Res* 2003 Jan;17(1):26-9. PubMed; PMID: 12557242.
80. Sobieraj DM, Freyer CW. Probable hypoglycemic adverse drug reaction associated with prickly pear cactus, glipizide, and metformin in a patient with type 2 diabetes mellitus. *Ann Pharmacother.* 2010 Jul-Aug; 44(7-8):1334-7. Epub 2010 Jun 1. PubMed; PMID: 20516361.
81. Ibañez-Camacho R, Roman-Ramos R. Hypoglycemic effect of *Opuntia* cactus. *Arch invest Med (Mex).* 1979; 10(4):223-30. PubMed; PMID: 539865.
82. Frati AC, Altamirano P, Ariza CR, Cortés-Franco R, Chávez-Negrete A, Islas-Andrade S. Influence of nopal intake upon fasting glycemia in type II diabetes and healthy subjects. *Arch Invest Med (Mex).* 1991 Jan-Mar; 22(1):51-6. PubMed; PMID: 1668138.
83. Luisa Tesoriere, Daniela Butera, Anna Maria Pintaudi, Mario Allegra, Maria A Livrea. Supplementation with cactus pear (*Opuntia ficus-indica*) fruit decreases oxidative stress in healthy humans: a comparative study with Vitamin C. *Am J Clin Nutr.* 2004;80:391-5.

84. Gentile C, Tesoriere L, Allegra M, Livera MA, D'Alessio P. Antioxidant betalains from cactus pear (*Opuntia ficus-indica*) inhibit endothelial ICAM-1 expression. *Ann N Y Acad Sci.* 2004 Dec; 1028:481-6. PubMed; PMID: 15650274.
85. Qiu Y, Chen Y, Pei Y, Matsuda H, Yoshikawa M. Constituents with radical scavenging effect from *Opuntia dillenii*: structures of new alpha-pyrone and flavonol glycoside. *Cem Pharm Bull (Tokyo).* 2002 Nov;50(11):1507-10. PubMed; PMID: 12419920.
86. Oh PS, Lim KT. Glycoprotein (90 kDa) isolated from *Opuntia ficus-indica* var. *saboten MAKINO* lowers plasma lipid level through scavenging of intracellular radicals in Triton WR-1339-induced mice. *Biol Pharm Bull.* 2006 Jul; 29(7): 1391-6. PubMed; PMID: 16819175.
87. Florian C. Stintzing, Kirsten M. Herbach, Markus R. Mosshammer, Reinhold Carle, Weiguang Yi, Subramani Sellappan, Casimir C. Akoh, Ron Bunch, Peter Felker. Color, Betalain Pattern, and Antioxidant Properties of Cactus Pear (*Opuntia* spp.) Clones. *J. Agric. Food Chem.* 2005, 53, 442-451.
88. Joseph O. Kutu. Antioxidant compounds from four *Opuntia* cactus pear fruit varieties. *Food Chemistry* 85 (2004) 527-533.
89. Butera D, Tesoriere L, Di Gaudio F, Bongiorno A, Allegra M, Pintaudi AM, Kohen R, Livrea MA. Antioxidant activities of sicilian prickly pear (*Opuntia ficus indica*) fruit extracts and reducing properties of its betalains: betanin and indicaxanthin. *J. Agric Food Chem.* 2002 Nov 6; 50(23):6895-901. PubMed; PMID: 12405794.
90. L. Tesoriere, M. Allegra, D. Butera, C. Gentile, M.A. Livrea. Kinetics of the lipoperoxyl radical-scavenging activity of indicaxanthin in solution and unilamellar liposomes. *Free radical Research*, 2006; 00(0): 1-8.
91. Lee EH, Kim HJ, Song YS, Jin C, Lee KT, Cho J, Lee YS. Constituents of the stems and fruits of *Opuntia ficus-indica* var. *saboten*. *Arch Pharm Res.* 2003 Dec; 26(12): 1018-23. PubMed; PMID: 14723334.
92. Chavez-Santoscoy RA, Gutierrez-Urbe JA, Serna-Saldívar SO. Phenolic composition, antioxidant capacity and in vitro cancer cell cytotoxicity of nine prickly pear (*Opuntia* spp.) juices. *Plant Foods Hum Nutr.* 2009 Jun; 64(2): 146-52. PubMed; PMID: 19468836.
93. Da-ming Zou, Molly Brewer, Francisco Garcia, Jean M Feugang, Jian Wang, Rounyu Zang, Huaguang Liu, Changping Zou. Cactus pear: a natural product in cancer chemoprevention. *Nutrition Journal* 2005, 4:25. doi: 10.1186/1475-2891-4-25. September 8, 2005.
94. Ji YB, Ji CF, Zou X, Gao Sy. [Study on the effects of two kinds of cactus polysaccharides on erythrocyte membrane protein and fluidity of the lipid in S180 mice]. *Zhongguo Zhong Yao Za Zhi.* 2004 Oct;29(10):967-70. PubMed; PMID: 15631085.
95. Srekanth D, Arunasree MK, Roy KR, Chandramohan Reddy T, Reddy GV, Reddanna P. Betanin a betacyanin pigment purified from fruits of *Opuntia ficus-indica* induces apoptosis in human chronic myeloid leukemia Cell line-K562. *Phytomedicine* 2007 Nov; 14(11):739-46. Epub 2007 May 7. PubMed; PMID: 17482444.
96. Ahmad A, Davies J, Randall S, Skinner GR. Antiviral properties of extract of *Opuntia streptacantha*. *Antiviral Res.* 1996 May; 30(2-3): 75-85. PubMed; PMID: 8783800.
97. Schepetkin IA, Xie G, Kirpotina LN, Klein RA, Jutila MA, Quinn MT. Macrophage immunodulatory activity of polysaccharides isolated from *Opuntia polyacantha*. *Int Immunopharmacol.* 2008 Oct; 8(10): 1455-66 Epub 2008 Jul 1. PubMed; PMID: 18597716.
98. Bergaoui A, Boughalleb N, Ben Jannet H, Harzallah-Shiric F, El Mahjoub M, Mighi Z. Chemical composition and antifungal activity of volatiles from three *Opuntia* species growing in Tunisia. *Pak J Biol Sci.* 2007 Aug 1; 10(15): 2485-9. PubMed; PMID: 19070119.
99. Trombetta D, Puglia C, Perri D, Licata A, Pergolizzi S, Lauriano ER, De Pasquale A, Saija A, Bonina FP. Effect of polysaccharides from *Opuntia ficus-indica* (L.) cladodes on the healing of dermal wounds in the rat. *Phytomedicine.* 2006 May; 13(5):352-8. Epub 2005 Sep 13. PubMed; PMID: 16635743.
100. Park EH, Chun MJ. Wound healing activity of *Opuntia ficus-indica*. *Fitoterapia* 2001 Feb; 72(2): 165-7. PubMed; PMID: 11223226.
101. Cho JY, Park SC, Kim TW, Kim KS, Song JC, Kim SK, Lee HM, Sung HJ, Park HJ, Song YB, Yoo ES, Lee CH, Rhee MH. Radical scavenging and anti-inflammatory activity of extracts from *Opuntia humifusa* Raf. *J Pharm Pharmacol.* 2006 Jan; 58(1): 113-9. PubMed; PMID: 16393471.
102. Park EH, Kahng JH, Lee SH, Shin KH. An anti-inflammatory principle from cactus. *Fitoterapia* 2001 Mar; 72(3): 288-90. PubMed; PMID: 11295308.
103. Bokov A, Chaudhuri A, Richardson A. The role of oxidative damage and stress in aging. *Mech Ageing Dev.* 2004 Oct-Nov; 125(10-11): 811-26. PubMed; PMID: 15541775.
104. Joseph Kanner, Stela Harel, Rina Granit. Betalains-A New Class of Dietary Cationized Antioxidants. *J. Agric. and Food Chem.* 2001, 49(11), pp5178-5185. DOI: 10.1021/jf010456f (Web): October 17, 2001.
105. Tesoriere L, Allegro M, Butera D, Livrea MA. Absorption, excretion, and distribution of dietary antioxidant betalains in LDLs: potential health effects of betalains in humans. *Am J Clin Nutr.* 2004;80:941-5.
106. Tesoriere L, Fazzari M, Angileri F, Gentile C, Livrea MA. In vitro digestion of betalianic foods. Stability and bioaccessibility of betaxanthins and betacyanins and antioxidative potential of food digesta. *J Agric Food Chem.* 2008 Nov 26;56(22): 10487-92. PubMed; PMID: 18959410.
107. Park EH, Kahng JH, Paek EA. Studies on the pharmacological action of cactus: identification of its anti-

- inflammatory effect. Arch Pharm Res. 1998 Feb; 21(1):30-4. . PubMed; PMID: 9875511.
108. Galati EM, Monforte MT, Tripodo MM, d'Aquino A, Mondello MR. Antiulcer activity of *Opuntia ficus indica* (L.) Mill. (Cactaceae): ultrastructural study. J Ethnopharmacol. 2001 Jun; 76(1):1-9. . PubMed; PMID: 11378276.
 109. Galati EM, Pergolizzi S, Miceli N, Monforte MT, Tripodo MM. Study on the increment of the production of gastric mucus in rats treated with *Opuntia ficus indica* (L.) Mill. Cladodes. J Ethnopharmacol. 2002 Dec; 83(3):229-33. . PubMed; PMID: 12426090.
 110. Lee EB, Hyun JE, Li DW, Moon YI. Effects of *Opuntia ficus-indica* var. Saboten stem on gastric damages in rats. Arch Pharm Res 2002 Feb;25(1):67-70. . PubMed; PMID: 11885695.
 111. Galati EM, Mondello MR, Guiffrida D, Dugo G, Miceli N, Pergolizzi S, Taviano MF. Chemical characterization and biological effects of Sicilian *Opuntia ficus indica* (L.) mill. Fruit juice: antioxidant and antiulcerogenic activity. J Agric Food Chem. 2003 Aug 13;51(17): 4903-8. . PubMed; PMID: 12903943.
 112. Vázquez-Ramírez R, Olguín-Martínez M, Kubli-Garfías C, Hernández-Muñoz R. Reversing gastric mucosal alterations during ethanol-induced chronic gastritis in rats by oral administration of *Opuntia ficus-indica* mucilage. World J Gastroenterol. 2006 Jul 21; 12(27):4318-24. PubMed; PMID: 16865772.
 113. Galati EM, Monforte MT, Miceli N, Mondello MR, Taviano MF, Galluzzo M, Tripodo MM. *Opuntia ficus indica* (L.) Mill. Mucilages show cytoprotective effect on gastric mucosa in rat. Phytother Res. 2007 Apr;21(4):344-6. PubMed; PMID: 17221828.
 114. Wiese J, McPherson S, Odden MC, Shlipak MG. Effect of *Opuntia ficus indica* on symptoms of the alcohol hangover. Arch Intern Med. 2004 Jun 28;164(12):1334-40. PubMed; PMID: 15226168.
 115. Pittler MH, Verster JC, Ernst E. Interventions for preventing or treating alcohol hangover: systematic review of randomized controlled trials. BMJ 2005 Dec 24;331(7531):1515-8. PubMed; PMID: 16373736.
 116. Wolfram R, Budinsky A, Efthimiou Y, Stomatopoulos J, Oguogho A, Sinzinger H. Daily prickly pear consumption improves platelet function. Prostaglandins Leukot Essent Fatty Acids. 2003 Jul; 69(1):61-6. PubMed; PMID: 12878452.
 117. Galati EM, Mondello MR, Lauriano ER, Taviano MF, Galluzzo M, Miceli N. *Opuntia ficus indica* (L.) Mill. Fruit juice protects liver from carbon tetrachloride-induced injury. Phytother Res. 2005 Sep; 19(9): 796-800. PubMed; PMID: 16220574.
 118. Ncibi S, Ben Othman M, Akacha A, Krifi MN, Zourgui L. *Opuntia ficus indica* extract protects against chlorpyrifos-induced damage on mice liver. Food Chem Toxicol. 2008 Feb; 46(2): 797-802. Epub 2007 Sep 14. PubMed; PMID: 17980473.
 119. Hfaiedh N, Allagui MS, Hfaiedh M, Feki AE, Zourgui L, Croute F. Protective effect of cactus (*Opuntia ficus indica*) cladode extract upon nickel-induced toxicity in rats. Food Chem Toxicol. 2008 Dec; 46(12): 3759-63. Epub 2008 Oct4. PubMed; PMID: 18950672.
 120. Zourgui L, Golli EE, Bouaziz C, Bacha H, Hassen W. Cactus (*Opuntia ficus-indica*) cladodes prevent oxidative damage induced by the mycotoxin zearalenone in Balb/C mice. Food Chem Toxicol. 2008 May;46(5):1817-24. Epub 2008 Jan 21. PubMed; PMID: 18313193.
 121. Zourgui L, Ayed-Boussema I, Ayed Y, Bacha H, Hassen W. The antigenotoxic activities of cactus (*Opuntia ficus-indica*) cladodes against the mycotoxin zearalenone in Balb/c mice: prevention of micronuclei, chromosome aberrations and DNA fragmentation. Food Chem Toxicol. 2009 Mar;47(3): 662-7. Epub 2008 Dec 27. PubMed; PMID: 19152824.
 122. Bisson JF, Daubié S, Hidago S, Guillemet D, Linares E. Diuretic and antioxidant effects of Cacti-Nea, a dehydrated water extract from prickly pear fruit, in rats. Phytother Res. 2010 Apr; 24(4): 587-94. PubMed; PMID: 19777503.
 123. Saleem R, Ahmed M, Azmat A, Ahmed SI, Faizi Z, Abidi L, Faizi S. Hypotensive activity, toxicology and histopathology of opuntioside-I and methanolic extract of *Opuntia dillenii*. Biol Pharm Bull. 2005 Oct;28(10): 1844-51. PubMed; PMID: 16204933.
 124. Schmitt L, Fouillot JP, Nicolet G, Midol A. *Opuntia ficus indica*'s effect on heart-rate variability in high-level athletes. Int J Sport Nutr Exerc Metab. 2008 Apr; 18(2): 169-78. PubMed; PMID: 18458360.
 125. Huang X, Li Q, Li H, Guo L. Neuroprotective and antioxidative effect of cactus polysaccharides in vivo and in vitro. Cell Mol Neurobiol. 2009 Dec;29(8): 1211-21. PubMed; PMID: 19517228.
 126. Dok-Go H, Lee KH, Kim HJ, Lee EH, Lee J, Song YS, Lee YH, Jin C, Lee YS, Cho J. Neuroprotective effects of antioxidative flavonoids, quercetin, (+)-dihydroquercetin and quercetin 3-methyl ether, isolated from *Opuntia ficus-indica* var. saboten. Brain Res. 2003 Mar 7;965(1-2): 130-6. PubMed; PMID: 12591129.
 127. Kim JH, Park SM, Ha HJ, Moon CJ, Shin TK, Kim JM, Lee NH, Kim HC, Jang
 128. KJ, Wie MB. *Opuntia ficus-indica* attenuates neuronal injury in vitro and in vivo models of cerebral ischemia. J Ethnopharmacol. 2006 Mar 8; 104(1-2):257-62. Epub 2005 Oct 21. PubMed; PMID: 16243466.
 129. Kim JM, Kim DH, Park SJ, Park DH, Jung SY, Kim HJ, Lee YS, Jin C, Ryu JH. The n-butanolic extract of *Opuntia ficus-indica* var. saboten enhances long-term memory in the passive avoidance task in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2010 May 20. [Epub ahead of print]. PubMed; PMID: 20493231.
 130. Rodriguez-Fragoso L, Rees-Esparza J, Burchiel SW, Herrera-Ruiz D, Torres E. Risks and benefits of commonly used

- herbal medicines in Mexico. *Toxicol Appl Pharmacol.* 2008 Feb 15;227(1): 125-35. Epub 2007 Oct 12. PubMed; PMID: 18037151.
131. Panico AM, Cardile V, Garufi F, Puglia C, Bonina F, Ronsisvalle S. Effect of hyaluronic acid and polysaccharides from *Opuntia ficus indica* (L.) cladodes on the metabolism of human chondrocyte cultures. *J Ethnopharmacol.* 2007 May 4; 111(2): 315-21. Epub 2006 Dec 2. PubMed; PMID: 17196777.
 132. Gliszczynska-Swiglo A, Szymusiak H, Malinowska P. Betanin, the main pigment of red beet: molecular origin of its exceptionally high free radical-scavenging activity. *Food Addit Contam.* 2006 Nov;23(11):1079-87. PubMed; PMID: 17071510.
 133. Jean Magloire Feugang, Patricia Konarski, Daming Zou, Florian Conrad Stintzing, Changping Zou. Nutritional and medicinal uses of Cactus pear (*Opuntia* spp.) cladodes and fruits. *Frontiers in Bioscience* 11, 2574-2589, September 1, 2006.
 134. Galati MG, Mondello MR, Monforte MT, Galluzzo M, Miceli N, Tripodo MM. Effect of *Opuntia ficus-indica* [L.] Mill. Cladodes in the Wound-Healing Process. *J.PACD-2003*, Vol 5. Pp 1-5. 2003 Journal of the Professional Association for Cactus Development.
 135. Livrea MA, Tesoriere L. Health Benefits and Bioactive Components of the Fruits from *Opuntia ficus-indica* [L.] Mill. *J. PACD- 2006*, Vol. 8. Pp 73-90. 200 Proceedings of the Professional Association for Cactus Development.
 136. Oguogho A, Efthimiou Y, Iliopoulos J, Stomatopoulos J, Ahmadzadehfar H, Schmid P, Steinbrenner D, Sinzinger H. Prickly pear changes indium-LDL and indium-HDL platelet binding correlating to improvement of platelet function in hypercholesterolemia. *J.PACD* (2010) 12:67-79.
 137. Fernández-López JA, Almela L, Obón JM, Castellar R. Determination of Antioxidant Constituents in Cactus Pear Fruits. *Plant Foods Hum Nutr* (2010) 65:253–259 DOI 10.1007/s11130-010-0189-x .Published online: 2 September 2010# Springer Science+Business Media, LLC 2010
 138. Bañuelos GS, Fakra SC, Walse SS, Marcus MA, Yang SI, Pickering IJ, Pilon-Smits EAH, Freeman JL. Selenium Accumulation, Distribution, and Speciation in Spineless Prickly Pear Cactus: A Drought- and Salt-Tolerant, Selenium-Enriched Nutraceutical Fruit Crop for Biofortified Foods. *Plant Physiology*, January 2011, Vol. 155, pp. 315–327, www.plantphysiol.org © 2010 American Society of Plant Biologists.
 139. Baldassano S, Tesoriere L, Rotondo A, Serio R, Livrea MA, Mule F. Inhibition of the Mechanical Activity of Mouse Ileum by Cactus Pear (*Opuntia Ficus Indica*, L, Mill.) Fruit Extract and Its Pigment Indicaxanthin. *J. Agric. Food Chem.* 2010, 58, 7565–7571 DOI:10.1021/jf100434e.
 140. Hahm S-W, Park J, Son Y-S. *Opuntia humifusa* Partitioned Extracts Inhibit the Growth of U87MG Human Glioblastoma Cells. *Plant Foods Hum Nutr* (2010) 65:247–252 DOI 10.1007/s11130-010-0188-y. Published online: 3 September 2010 # Springer Science+Business Media, LLC 2010.
 141. Butterweck V, Semlin L, Feistel B, Pischel I, Bauer K, Verspohl EJ. Comparative Evaluation of Two Different *Opuntia ficus-indica* Extracts for Blood Sugar Lowering Effects in Rats. *PHYTOTHERAPY RESEARCH Phytother. Res.* 25: 370–375 (2011) Published online 4 August 2010 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/ptr.3271.
 142. Godard MP, Ewing BA, Pischel I, Ziegler A, Benedek B, Feistel B. Acute blood glucose lowering effects and long-term safety of *Opuntia* supplementation in pre-diabetic males and females. *J Ethnopharmacol.* 2010 Aug 9;130(3):631-4. Epub 2010 Jun 4. PMID: 20621660.
 143. Alimi H, Hfaiedh N, Bouoni Z, Hfaiedh M, Sakly M, Zourgui L, Rhouma KB. Antioxidant and antiulcerogenic activities of *Opuntia ficus indica* f. *inermis* root extract in rats. *Phytomedicine*, 2010 Dec 1;17(14):1120-6. Epub 2010 Jul 16. PMID: 20638261.
 144. Sánchez E, García S, Heredia N. Extracts of edible and medicinal plants damage membranes of *Vibrio cholerae*. *Appl Environ Microbiol.* 2010 Oct;76(20):6888-94. Epub 2010 Aug 27. PMID: 20802077.
 145. Andrade-Cetto A, Wiedenfeld H. Anti-hyperglycemic effect of *Opuntia streptacantha* Lem. *J Ethnopharmacol.* 2011 Jan 27;133(2):940-3. Epub 2010 Nov 25. PMID: 21111796.
 146. Luo C, Zhang W, Sheng C, Zheng C, Yao J, Miao Z. Chemical composition and antidiabetic activity of *Opuntia Milpa Alta* extracts *Chem Biodivers.* 2010 Dec;7(12):2869-79. PMID: 21161999.
 147. Zhao LY, Lan QJ, Huang ZC, Quyang LJ, Zeng FH. Antidiabetic effect of a newly identified component of *Opuntia dillenii* polysaccharides. *Phytomedicine.* 2011 Feb 5. [Epub ahead of print] PMID: 21300531.
 148. Mongi S, Jebahi S, Jamoussi K, Ben Salah G, Kallel C, El Feki A. Haematological and biochemical toxicity induced by methanol in rats: ameliorative effects of *Opuntia vulgaris* fruit extract. *Hum Exp Toxicol.* 2011 Mar 21. [Epub ahead of print] PMID: 21422078.